Eyebot, a pioneering vision care startup, has raised $20 million in a Series A funding round to expand access to eye care through innovative technology.
The round, led by General Catalyst, aims to accelerate the deployment of Eyebot's groundbreaking 90-second vision test kiosks, which deliver doctor-verified glasses prescriptions without the need for an on-site optometrist.
Breaking Barriers in Vision Care Accessibility
This funding milestone, announced on August 26, 2025, marks a significant step toward addressing the global challenge of limited access to eye care services.
Over half of Americans rely on corrective eyewear, yet many face barriers such as long wait times, high costs, and geographic limitations when seeking prescriptions.
A History of Innovation in Eye Care
Eyebot's journey began with a mission to democratize vision care, building on earlier successes like a $6 million seed round in June 2024 to roll out its AI-powered kiosks.
The company's technology represents a leap forward from traditional optometry, offering a self-serve solution that combines artificial intelligence with medical validation.
The Impact of Eyebot's Technology
By placing kiosks in accessible locations like malls and pharmacies, Eyebot is poised to serve underserved communities, reducing the burden on overbooked eye care professionals.
Partnerships, such as the one with Zenni Optical announced in October 2024, further amplify its reach by connecting users to affordable eyewear options post-diagnosis.
Future Prospects for Eyebot and Vision Care
Looking ahead, Eyebot plans to use the $20M funding to scale operations, expand kiosk networks, and refine its technology for even faster and more accurate diagnostics.
The potential to integrate additional health screenings into these kiosks could position Eyebot as a broader health tech innovator in the coming years.
Industry experts believe this model could inspire similar disruptions in other healthcare sectors, setting a precedent for automated, accessible medical services.
As Eyebot continues to grow, its vision of 'care at the speed of sight' may soon become a reality for millions worldwide.
Maria Lourdes
